IMNM 12.13 Immunome, Inc.
| Range: | 6.93-30.958 | Vol Avg: | 647979 | Last Div: | 0 | Changes: | 0.36 |
| Beta: | 1.77 | Cap: | 0.73B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 02 2020 | Empoloyees: | 78 | ||
| CUSIP: | 45257U108 | CIK: | 0001472012 | ISIN: | US45257U1088 | Country: | US |
| CEO: | Dr. Clay B. Siegall Ph.D. | Website: | https://immunome.com | ||||
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Stock Details
IMNM 23
Immunome price target lowered to $23 from $27 at Piper Sandler
Biren Amin·Tue Aug 13 2024
Piper Sandler
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow